Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting

This article was originally published in The Pink Sheet Daily

Executive Summary

The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.

You may also be interested in...



Eagerly Awaited Expanded Xtandi Label Should Accelerate Sales

Medivation had already expanded its enzalutamide sales force to complement partner Astellas’ team ahead of getting a new indication for the earlier, pre-chemotherapy prostate cancer setting. The expanded label now paves the way for reps to drop in on more urologists.

Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J&J

Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.

Deals Of The Week Looks At 2014 Takeout Targets

The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel